NYSE:NNVC NanoViricides (NNVC) Stock Price, News & Analysis $1.23 -0.12 (-8.89%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$1.31 +0.08 (+6.26%) As of 11/13/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About NanoViricides Stock (NYSE:NNVC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NanoViricides alerts:Sign Up Key Stats Today's Range$1.21▼$1.3550-Day Range$1.02▼$1.6952-Week Range$0.85▼$1.93Volume171,037 shsAverage Volume492,089 shsMarket Capitalization$31.40 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingBuy Company Overview NanoViricides, Inc. is a biotechnology company focused on developing antiviral treatments using its nanoviricide technology. The company’s approach is designed to target and bind to viruses, with the goal of neutralizing them or preventing them from infecting cells. The company’s research programs include NV-387, a candidate being developed for respiratory viral infections, as well as programs targeting other viruses, including herpesviruses and HIV. These candidates remain in development, and their availability as treatments depends on further research and regulatory review. Founded in 2005 and based in Shelton, Connecticut, NanoViricides is focused on developing potential therapies for viral diseases. Its work is conducted in the United States, with research aimed at diseases that affect patients worldwide.AI Generated. May Contain Errors. Read More NanoViricides Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreNNVC MarketRank™: 1.266438716465 of 5 starsNanoViricides scored higher than 25% of companies evaluated by MarketBeat, and ranked 794th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNanoViricides has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and no sell ratings.Upside PotentialNanoViricides has a consensus price target of $6.00, representing about 387.8% upside from its current price of $1.23.Amount of Analyst CoverageNanoViricides has received no research coverage in the past 90 days.Read more about NanoViricides' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of NanoViricides is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NanoViricides is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNanoViricides has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for NNVC. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNanoViricides does not currently pay a dividend.Dividend GrowthNanoViricides does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for NanoViricides this week, compared to 1 article on an average week.Search InterestOnly 11 people have searched for NNVC on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.MarketBeat Follows9 people have added NanoViricides to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NanoViricides insiders have not sold or bought any company stock.Percentage Held by Insiders2.80% of the stock of NanoViricides is held by insiders.Percentage Held by Institutions10.30% of the stock of NanoViricides is held by institutions.Read more about NanoViricides' insider trading history. Receive NNVC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NanoViricides and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NNVC Stock News HeadlinesAn Investigational Drug to Tackle Measles OutbreaksNovember 10, 2026 | finance.yahoo.comAs Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Overstated — Phase II Clinical Trial Advancing Toward the Second Part, Says ...October 27, 2026 | reuters.comUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.November 15 at 1:00 AM | Digest Publishing (Ad)As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated – Phase II Clinical Trial Advancing Towards the Second Part ...October 27, 2026 | usatoday.comAs Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says ...October 27, 2026 | finance.yahoo.comNanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal ...October 20, 2026 | finance.yahoo.comNanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over ...October 5, 2026 | theglobeandmail.comClinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week, Says NanoViricidesSeptember 29, 2026 | marketscreener.comMSee More Headlines NNVC Stock Analysis - Frequently Asked Questions How have NNVC shares performed this year? NanoViricides' stock was trading at $1.13 at the beginning of the year. Since then, NNVC shares have increased by 8.8% and is now trading at $1.23. How were NanoViricides' earnings last quarter? NanoViricides, Inc. (NYSE:NNVC) issued its earnings results on Friday, September, 27th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.01. When did NanoViricides' stock split? Shares of NanoViricides reverse split before market open on Tuesday, September 24th 2019.The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 23rd 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are NanoViricides' major shareholders? NanoViricides' top institutional shareholders include Miller Financial Services LLC (0.52%), State Street Corp (0.21%) and Empowered Funds LLC (0.14%). View institutional ownership trends. How do I buy shares of NanoViricides? Shares of NNVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NanoViricides own? Based on aggregate information from My MarketBeat watchlists, some other companies that NanoViricides investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Palantir Technologies (PLTR), Intel (INTC), Taiwan Semiconductor Manufacturing (TSM) and Inovio Pharmaceuticals (INO). Company Calendar Today11/15/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 NNVC's financial health is in the Green zone, according to TradeSmith. NNVC has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:NNVC CIK1379006 Webwww.nanoviricides.com Phone(203) 668-5580Fax203-859-5095Employees7Year Founded2005Price Target and Rating Average Price Target for NanoViricides$6.00 High Price Target$6.00 Low Price Target$6.00 Potential Upside/Downside+387.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.29 million Net MarginsN/A Pretax MarginN/A Return on Equity-87.90% Return on Assets-78.69% Debt Debt-to-Equity RatioN/A Current Ratio3.44 Quick Ratio2.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.66 per share Price / Book1.86Miscellaneous Outstanding Shares25,525,000Free Float14,922,000Market Cap$31.40 million OptionableOptionable Beta1.82 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NYSE:NNVC) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NanoViricides, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NanoViricides With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.